• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 01, 2022 at 10:32: AM
via While Biogen was moved to reanalyse two failed pivotal studies and cherrypick data from one to back the controversial approval of Aduhelm, its competitor Roche proceeded rather differently. The Swiss group took under three weeks to decide that the Graduate 1 and 2 trials warranted shutting down its gantenerumab programme entirely, CTAD heard last night.

article source
 




Top Bottom
Back
Quote